On July 20, Pharmaron rose 5.69% in regular trading, trading at 24.48 HKD/share, with turnover of approximately 73.97 million HKD.

The rally was driven by the company's recently disclosed H1 earnings forecast exceeding market expectations, combined with a broad recovery in CRO industry orders. Pharmaron guided H1 revenue of 7.47-7.67 billion yuan, up 16%-19% YoY, and attributable net profit of 729-772 million yuan, up 4%-10% YoY. Notably, newly signed orders surged over 30% YoY, with small-molecule CDMO new orders jumping over 50%, while Q2 performance showed clear acceleration versus Q1.

At the industry level, CRO sector orders have broadly recovered, with leading companies reporting backlog growth exceeding 40% YoY. Analysts believe the CXO rebound is backed by solid earnings fundamentals. Additionally, JP Morgan recently increased its stake by approximately 1.29 million shares at around 22.11 HKD per share, while Daiwa initiated coverage with a Buy rating and a target price of 25.5 HKD.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)